Lusvertikimab posts strong phase II ulcerative colitis results, advancing
Lusvertikimab, an anti-IL-7 receptor antibody, reported robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic and histological endpoints. Development is advancing into pouchitis trials.